Torbay Pharmacy Manufacturing Unit appoints md

Dr Nick Frampton to run the unit

The UK’s South Devon Healthcare NHS Foundation Trust has appointed Dr Nick Frampton as managing director of the Torbay Pharmacy Manufacturing Unit (PMU), which produces licensed pharmaceuticals, pharmaceutical specials and medical devices.

Frampton joins the firm from Advanced Medical Solutions Group, where he was vice president of sales and marketing and contributed to a period of double-digit growth. He has formerly held quality, technical and commercial roles at West Pharmaceutical Services, Ernest Jackson and Banner Pharmacaps.

You may also like

Finance

NorthEdge invests in sterile injectable CMO to accelerate international growth

Private equity firm NorthEdge has invested in sterile injectable contract manufacturer and licence holder, Torbay Pharmaceuticals (Torbay), to support its next phase of international growth
Finance

Genmab to acquire Merus in $8bn deal to expand late-stage pipeline

The acquisition adds breakthrough therapy petosemtamab to Genmab’s portfolio, accelerating its shift to a wholly owned model and supporting multiple new drug launches by 2027
Finance

New CGT centre in Bangkok to boost Southeast Asia’s biotech ecosystem

eXmoor Pharma and Siam Bioscience form a strategic partnership to establish leading cell and gene therapy services in Southeast Asia
Finance

Pfizer to acquire Metsera in $4.9bn deal, expanding obesity drug pipeline with next-generation incretin and amylin therapies

The deal strengthens Pfizer’s position in the fast-growing obesity market, with additional milestone payments of up to $2.3bn tied to key clinical and regulatory achievements
Finance

DaltonTx secures £4m in seed financing to build adaptive, AI-enabled discovery platforms

The UK-based technology company's adaptive platform will plug directly into pharma, biotech and CRO workflows, giving teams instant access to AI-enabled discovery
Manufacturing

Prange Pharma to acquire MSD Animal Health manufacturing site in Aprilia, Italy

Following completion, the site will relaunch as Aprilia Animal Health, focussing on contract manufacturing of animal health products whilst preserving jobs and expanding European expertise
Finance

EMV Capital subsidiary Moirai acquires Destiny Pharma’s XF-73 antibiotic platform

The XF drug platform, designed to prevent bacterial resistance and combat Gram-positive infections such as MRSA, represents a high-impact addition to EMV’s life sciences portfolio
Subscribe now